MB

MPM BioImpact Portfolio holdings

AUM $874M
1-Year Est. Return 79.23%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+79.23%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$611M
AUM Growth
+$33.7M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
51
New
Increased
Reduced
Closed

Top Buys

1
+$18M
2
+$7.41M
3
+$6.74M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$6.34M
5
LQDA icon
Liquidia Corp
LQDA
+$4.34M

Top Sells

1
+$23M
2
+$14.8M
3
+$14.8M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$12.3M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$10.1M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
26
Wave Life Sciences
WVE
$1.43B
$11M 1.8%
1,505,262
DBVT
27
DBV Technologies
DBVT
$1.26B
$10.5M 1.73%
1,054,504
SLNO icon
28
Soleno Therapeutics
SLNO
$2.72B
$10.1M 1.66%
150,000
+100,000
SLDB icon
29
Solid Biosciences
SLDB
$819M
$10.1M 1.65%
1,634,569
AKBA icon
30
Akebia Therapeutics
AKBA
$415M
$7.89M 1.29%
2,889,125
HOWL icon
31
Werewolf Therapeutics
HOWL
$44.7M
$4.75M 0.78%
2,408,810
LQDA icon
32
Liquidia Corp
LQDA
$3.54B
$4.55M 0.74%
+200,000
PVLA
33
Palvella Therapeutics
PVLA
$1.84B
$4.23M 0.69%
+67,423
DSGN icon
34
Design Therapeutics
DSGN
$786M
$4.18M 0.68%
555,187
RNAC icon
35
Cartesian Therapeutics
RNAC
$159M
$3.88M 0.64%
380,000
-306,007
ENGN icon
36
enGene Therapeutics Inc. Common Stock
ENGN
$520M
$3.62M 0.59%
+530,299
URGN icon
37
UroGen Pharma
URGN
$1.05B
$2.69M 0.44%
+135,000
RAPP
38
Rapport Therapeutics
RAPP
$1.75B
$2.13M 0.35%
+71,807
RPTX
39
DELISTED
Repare Therapeutics
RPTX
$1.44M 0.24%
819,924
ASMB icon
40
Assembly Biosciences
ASMB
$473M
$1.02M 0.17%
+39,665
ACLX icon
41
Arcellx
ACLX
$6.73B
– –
-37
ADAP
42
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-4,411,821
CRNX icon
43
Crinetics Pharmaceuticals
CRNX
$4.16B
– –
-428,975
GH icon
44
Guardant Health
GH
$11.1B
– –
-442,656
MLTX icon
45
MoonLake Immunotherapeutics
MLTX
$1.29B
– –
-313,571
NUVB icon
46
Nuvation Bio
NUVB
$1.68B
– –
-4,622,590
OLMA icon
47
Olema Pharmaceuticals
OLMA
$1.44B
– –
-2,378,762
REPL icon
48
Replimune Group
REPL
$188M
– –
-983,780
TSHA icon
49
Taysha Gene Therapies
TSHA
$1.72B
– –
-2,953,562
VERU icon
50
Veru
VERU
$39M
– –
-491,195
1
2
3